在未来的研究中,需要招募和随访更多患者,以探索BCMA/GPRC5D双特异性CAR-T细胞治疗的长期结果和晚期毒性。 参考文献:Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-...
1.Zhou D, et al. Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial.Lancet Haematol . 2024 Jul 23:S2352-3026(24)00176...
2024年7月24日,徐州医科大学附属医院血液科李振宇、徐开林团队与上海雅科生物科技有限公司合作,在国际知名期刊Lancet Haematology发表了题为“Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 1 trial”的临床试验研究成果。徐医附院血液科周典...
2024年7月23日,采用上海雅科生物科技有限公司研发的BCMA/GPRC5D双特异CAR-T细胞治疗技术 (YK-BCMA-GPRC5D BoomTM, YK-CAR-069),由徐州医科大学血液病研究所医疗团队进行I期临床试验的研究成果在国际知名期刊发表[2]:Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple ...
Despite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BC
Chimeric antigen receptor (CAR) T cells and bispecific T cell engagers have become integral components in the treatment of relapsed/refractory multiple myeloma. We report a 63-year-old male who received ciltacabtagene autoleucel CAR T cells and the GPRC5D 脳 CD3 bispecific talquetamab for ...
Targeted immunotherapies have ushered in a transformative era in multiple myeloma (MM) treatment, with chimeric antigen receptor T cells (CAR T) and bispecific T-cell engagers (TCEs) at the forefront. These T-cell immunotherapies are rapidly advancing to address unmet needs within the MM treatment...
缔码授权GPRC5D分子后,合作方反馈一例GPRC5D CAR-T IIT临床效果 Figure5. A RRMM patient relapsed from BCMA CAR T-cell therapy was treated with our anti-GPRC5D CAR T-cells. A metastatic tumor of large size behind patient ear nearly disappeared in 10 days after CAR T-cells infusion. (Curren...
BCMA and GPRC5D are overexpressed in myeloma cells. Although CAR-T and T cell engager (TCE) targeting BCMA or GPRC5D have been efficacious in MM patients, resistance does occur. Since the expression of BCMA and GPRC5D in MM are heterogeneous, to further improve the overall response and ...
开展以CAR-T细胞免疫治疗为核心的新型靶向整体治疗模式,取得了显著的成绩。本届ASH年会,邱玲医生代表团队投稿的《A Single-Center, Single-Arm, Phase I Clinical Trial of Anti-BCMA/GPRC5D Bispecific CAR T-Cells in Patients with...